Diligence memo · auto-generated · as of July 2, 2026

CinCor Pharma, Inc.

CinCor Pharma, Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

CinCor Pharma, Inc. operates in Biotechnology, based in CINCINNATI.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

CinCor Pharma, Inc. has raised $143M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).

Largest single filing: $143M on 2021-09-22.

Most recent recorded round closed around 2021-09-22.

Valuation (modeled)modeled

Provath models CinCor Pharma, Inc. at approximately $3.9B (range $648M–$7.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.93× the median modeled value of Series D+ Biotechnology companies in 2019–2021 (58 peers) — value vs value, same stage and era. Within the normal band (93% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 4.8 yr ago; this sector typically re-raises about every 14 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 94% of Biotechnology peers (4293 compared).

Modeled value ranks above 98% of those peers.

Closest niche peers: Sarepta Therapeutics, Inc., Asklepios BioPharmaceutical, Inc., Affinivax, Inc., Sonoma Biotherapeutics, Inc., Instil Bio, Inc..

Peoplefiled

1 named person on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.